Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?

Albandar, Heidar J; Fuqua, Jacob; Albandar, Jasim M; Safi, Salahuddin; Merrill, Samuel A; Ma, Patrick C

Albandar, Heidar J; Fuqua, Jacob; Albandar, Jasim M; Safi, Salahuddin; Merrill, Samuel A; Ma, Patrick C.

Afiliación

Albandar HJ; West Virginia University Cancer Institute, Morgantown, WV 26506, USA.
Fuqua J; Department of Medicine, West Virginia University, Morgantown, WV 26506, USA.
Albandar JM; Department of Periodontology and Oral Implantology, Temple University School of Dentistry, Philadelphia, PA 19140, USA.
Safi S; West Virginia University Cancer Institute, Morgantown, WV 26506, USA.
Merrill SA; West Virginia University Cancer Institute, Morgantown, WV 26506, USA.
Ma PC; Penn State Cancer Institute, Penn State College of Medicine, Penn State Health Milton S. Hershey Medical Center, Pennsylvania State University, Hershey, PA 17033, USA.

Cancers (Basel) ; 13(5)2021 Feb 27.

Article en En | MEDLINE | ID: mdl-33673446

Palabras clave

checkpoint inhibitor; immune related adverse event; rechallenge of immunotherapy

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Guideline Idioma: En Revista: Cancers (Basel) Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google